# Progyny

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/progyny

- Industry: Healthcare
- Headquarters: New York, US
- Website: www.progyny.com
- Total disclosed funding: $103M
- Latest round: Series B (May 2, 2017)
- Investors on record: 8

## About

Progyny, Inc. is a US-based company specializing in comprehensive benefits focused on women’s health and family building, offering tailored solutions for reproductive health from preconception to menopause.Founded in 2015 and headquartered in New York, US, Progyny, Inc. operates as a provider of fertility and family planning benefits. Its CEO is David Schlanger. Progyny has undergone significant growth, culminating in an IPO on October 24, 2019, where it raised USD 130 mn, marking a pivotal moment in its business trajectory. The company has successfully completed 10 deals since its inception, expanding its market presence and client base.Progyny specializes in comprehensive benefits that support women’s health and family building. Their offerings include fertility and family planning benefits, pregnancy and postpartum care, and menopause resources, aimed at enhancing clinical outcomes through a network of over 1,000 specialized providers. Progyny caters to over 530 client organizations across various industries, primarily in the United States, using a robust digital platform and high-touch support from dedicated Progyny Care Advocates.In the most recent fiscal year of 2023, Progyny reported a revenue of USD 1,088.60 mn and an EBITDA of USD 64.46 mn. The company's revenue generation model is B2B, focusing on integrated health benefits for women's health and family building services. Employers subscribe to Progyny’s comprehensive benefit packages, which include personalized support for employees navigating reproductive health issues.Following its IPO in October 2019, where Progyny raised USD 130 mn, the company plans to utilize these funds to enhance its service offerings. Progyny aims to expand its product suite, with new services targeting fertility technology expected to launch by 2024. Additionally, the company is exploring international markets, with plans for expansion into Europe and Asia by 2025, aiming to adapt its offerings to meet diverse regional needs.

## Funding rounds

- Series B, May 2, 2017, $10M — Kleiner Perkins, SR One, TPG Biotech
- Series B, Jun 15, 2016, $15M — Kleiner Perkins, SR One, TPG Biotech, M Ventures, Mellon Ventures, Union Grove Venture Partners
- Series B, Mar 4, 2015, $34M — Kleiner Perkins, TPG Biotech, M Ventures
- Series B, Sep 6, 2013, $5.5M — Kleiner Perkins, M Ventures, TPG PEP
- Series B, Jul 24, 2013, $0.5M — Kleiner Perkins
- Series B, May 30, 2012, $18M — Kleiner Perkins, TPG, M Ventures
- Series A, Feb 2, 2012, $6M — Kleiner Perkins, TPG Biotech, M Ventures
- Series A, May 25, 2010, $14M — Kleiner Perkins, TPG Biotech, M Ventures

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A, Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A, Series B
- TPG (https://capitalatlas.ai/funds/tpg) — Series B
- TPG PEP — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B
- Mellon Ventures (https://capitalatlas.ai/funds/mellon-ventures) — Series B
- Union Grove Venture Partners (https://capitalatlas.ai/funds/union-grove-venture-partners) — Series B